Ann: Immuron CEO to Present at RedChip Global Online Growth Conf, page-8

From the Red Chip website on IMU  - also there is  a Youtube  vid of the interview with the Jerry Kenallis  back in  Nov 2017 .

Since that interview there has been  a number of very positive announcements  over the last 5 months .




The interview tomorrow -  should be quite good , as everything that was mentioned back in Nov  has happened ( pretty much )

Thats a good thing ...in that the take away message should be  "on track  & making good progress "



INVESTMENT HIGHLIGHTS

• In March 2018, Immuron reported positive top line Phase 2 results in a NASH clinical study
  • NASH therapies are estimated to become a $40 billion global market by 2025
  • Results demonstrate excellent safety and tolerability
  • Statistically significant reduction of additional serum NASH biomarkers associated with liver damage – AST and CK-18
  • Statistically significant reduction in serum endotoxin/lipopolysaccharide (LPS) levels compared to placebo

• Immuron is in three Phase 2 clinical trials for NASH, ASH, and pediatric NAFLD

• Revenue increased 40% to AUD1.4 million in FY17, up from AUD1 million in FY16
  • Current revenue generated from Travelan, an all-natural OTC product for the prevention of traveler’s diarrhea
  • Global market estimate of between $600 million and $1.2 billion for Travelan
  • Currently licensed in the U.S., Australia, Canada, South Africa, Latin America, and several countries in Southeast Asia

• IMRN’s IMM-529 program has the potential to be the top therapy for Clostridium difficile infection (CDI)
  • Phase 1 trials to begin at Hadassah Medical center to enroll patients in 2H17; received approval from Israeli Minister of Health
  • Preclinical results showed 80% efficacy for the prevention and treatment of CDI and 77.8% prevention of infection recurrence in mice